Neurophysin I: a reliable, novel, and robust biomarker for oxytocin
These results validate NP-I as a biomarker for endogenous OXT secretion after stimulation with MDMA, addressing long-standing challenges in direct OXT measurement. NP-I offers novel opportunities for research in conditions where reduced OXT levels or disruptions in signaling are implicated, such as autism spectrum disorder, anxiety, and depression.
Authors
- Cihan Atila (ORCID: https://orcid.org/0000-0002-5442-7304)
- Svenja Leibnitz (ORCID: https://orcid.org/0009-0000-2643-0111)
- Matthias E. Liechti (ORCID: https://orcid.org/0000-0002-1765-9659)
- Mirjam Christ‐Crain (ORCID: https://orcid.org/0000-0002-6336-0965)
- Andi Nikaj (ORCID: https://orcid.org/0009-0005-2294-9262)
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
- Hospital Base (CL)
- Department of Biomedicine Basel (CH)
Publication Details
- Journal
- European Journal of Endocrinology
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1093/ejendo/lvaf078
- Citations
- 9
- Primary Topic
- Neuroendocrine regulation and behavior
- Type
- article
- Field-Weighted Citation Impact
- 21.95
Funders
- National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Schweizerische Akademie der Medizinischen Wissenschaften